Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection

참고문헌 (9)

1. Ghany MG, "Hepatitis C Guidance 2019 Update : American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection", Hepatology, 71, pp.686~721 (2020)
2. World Health Organization, "Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis", World Health Organization, 1~56 (2021)
3. Liang TJ, "Controlled human infection model-fast track to HCV vaccine?", N Engl J Med, 385, pp.1235~1240 (2021)
4. European Association for the Study of the Liver, "Electronic address : easloffice@easloffice. eu; Clinical Practice Guidelines Panel : Chair : ; EASL Governing Board representative : ; Panel members : . EASL recommendations on treatment of hepatitis C : Final update of the series☆", J Hepatol, 73, pp.1170~1218 (2020)
5. D’Ambrosio R, "Real-world effectiveness and safety of glecaprevir", pibrentasvir in 723 patients with chronic hepatitis C, 2019, pp.70, 379~387
6. "FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease"[URL]
7. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)
8. Bourlière M, "Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection", N Engl J Med, 376, pp.2134~2146 (2017)
9. Jeong Heo, "Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study", The Korean Journal of Internal Medicine, 38(4), pp.504~513 (2023), 대한내과학회

관련 논문AI추천